Company: PRME
Filing Date: 2025-11-07
Form Type: 10-Q
Source: 0001628280-25-050422
Chunk: 21

Company: Prime Medicine, Inc.
Filing Date: 2025-11-07
Form: 10-Q
Item: Part I, Item 1
Chunk 21
---
,(in thousands, except share and per share amounts)2025202420252024Revenue:Collaboration revenue — related party$1,179 $— $3,748 $— Collaboration revenue46 209 46 800 Total revenue1,225 209 3,794 800 Operating expenses:Research and development43,990 40,340 125,927 121,185 General and administrative11,208 14,101 37,609 37,860 Total operating expenses55,198 54,441 163,536 159,045 Loss from operations(53,973)(54,232)(159,742)(158,245)Other income:Interest income1,141 697 3,066 1,984 Accretion (amortization) of investments752 885 1,621 3,201 Change in fair value of short-term investment — related party1,454 215 (107)(544)Other income, net44 (83)99 (2)Total other income, net3,391 1,714 4,679 4,639 Net loss attributable to common stockholders$(50,582)$(52,518)$(155,063)$(153,606)Net loss per share attributable to common stockholders, basic and diluted$(0.32)$(0.44)$(1.11)$(1.34)Weighted-average common shares outstanding, basic and diluted160,503,183 119,764,270 139,244,743 114,492,416 Comprehensive loss:Net loss$(50,582)$(52,518)$(155,063)$(153,606)Change in unrealized loss on investments, net of tax43 92 32 36 Comprehensive loss$(50,539)$(52,426)$(155,031)$(153,570)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 

6

PRIME MEDICINE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(Unaudited)

Common StockAdditionalPaid-inCapitalAccumulated OtherComprehensiveLossesAccumulatedDeficitTotalStockholders’Equity(in thousands, except share amounts)SharesAmountBalance as of December 31, 2024131,160,842 $2 $